In another study, the MEK inhibitor binimetinib reduced cell proliferation and survival in CLL cells under conditions that mimic the tumour microenvironment, and sensitized CLL cells to the BH3-mimetics ABT-737 and venetoclax [177]. This evidence concerns the gene MAP2K7 and B-cell chronic lymphocytic leukemia.